
Novartis has released new data demonstrating the efficacy of Xolair (omalizumab) in the treatment of chronic spontaneous urticaria (CSU), a …
Aiforia deal to expand access to pathology AI
SMC accepts atogepant for acute migraine treatment in Scotland
New CCO Ogburn joins Cori Clinical

